Trials / Completed
CompletedNCT03687099
Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Despite advances in neurosurgery , radiotherapy and chemotherapy, the median survival in GBM patients is only 15 months from diagnosis. Immunotherapy by checkpoint inhibitors (PD1 /PDL-1) appears as a promising treatment for many cancers. However, first clinical results are disappointing for GBM. An hypothesis is the immunosuppressive activity from infiltrating non-tumor cells. Conversion of non-tumor cells from an immunosuppressive to an immuno-activating phenotype could be attempted in a therapeutic perspective.
Detailed description
An important and constant infiltration of cells marked with CD45 has been observed in 77 GBM studied for the prognostic value of PDL1 and IL17 infiltration (in association with Pr Ghiringhelli ; INSERM ; Dijon) . However, CD45 is present at the surface of all leucocytes. The purpose of this project is to better characterize the nature and functionality of the CD45+ cells that infiltrate GBM (lymphocytes and their sub-types, macrophages, microglial cells). Formalin-fixed paraffin-embedded GBM samples will be studied. A panel of immune cell antibody will be used for the immuno-histological (IH) study. Furthermore, the investigator will compare these data with those obtained by the nanoString technology, a multiplexed measurement of gene expression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival |
Timeline
- Start date
- 2018-04-30
- Primary completion
- 2019-11-08
- Completion
- 2019-11-08
- First posted
- 2018-09-27
- Last updated
- 2020-07-16
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03687099. Inclusion in this directory is not an endorsement.